FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program

Plus, news about Nuvalent and Phrontline: 🟢 FDA clears Sarepta’s next step: Sarepta said it will study its Duchenne muscular dystrophy gene therapy Elevidys with a new ...